Memory Pharmaceuticals

Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March...

yahoo.com     Feb 28, 2008   4 related          

Memory Pharmaceuticals Corp. announced today that it will report its fourth quarter and full year 2007 financial results on Thursday, March 6, 2008, before the U.S. financial markets open. ... Thursday February 28, 6:05 am ET MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/...                    

comments

Market Review: Progressive Review for Memory Pharmaceuticals Corp.

tmcnet.com     Feb 28, 2008   31 related          

Market Review: Progressive Review for Memory Pharmaceuticals Corp. ... (M2 PressWIRE Via Thomson Dialog NewsEdge) Streetinvesting.com has now resumed our progressive review of Memory Pharmaceuticals Corp. (Nasdaq: MEMY) after it traded unchanged Thursday, early in the...                    

comments

Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen

impactwire.com     Feb 25, 2008          

Amgen Also Increases Research Funding Commitment for Collaboration ... MONTVALE, N.J., September 28 /Impact Wire/ -- Memory Pharmaceuticals Corp. (MEMY) today announced that it has achieved a $2.0 million milestone related to its PDE10 collaboration with Amgen, a...                    

comments

Memory Pharmaceuticals & Roche Expand Development Program For MEM 3454 In Schizophrenia

medicalnewstoday.com     Feb 25, 2008   1 related          

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia.                    

comments

Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen

impactwire.com     Feb 21, 2008          

Amgen Also Increases Research Funding Commitment for Collaboration ... MONTVALE, N.J., September 28 /Impact Wire/ -- Memory Pharmaceuticals Corp. (MEMY) today announced that it has achieved a $2.0 million milestone related to its PDE10 collaboration with Amgen, a...                    

comments

Memory Pharmaceuticals Corp. (MEMY) Corporate Event Announcement Notice

pharmiweb.co.uk     Feb 21, 2008          

TradingMarkets ... .com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any...                    

comments

Memory to initiate schizophrenia biomarker study

pharmaceutical-business-review.com     Feb 20, 2008   12 related          

Memory Pharmaceuticals has announced that it plans to conduct a clinical study of MEM 3454, the company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia.                    

comments

IST Market Review: Introduces Memory Pharmaceuticals to our Bluechips Radar

tmcnet.com     Feb 20, 2008   11 related          

IST Market Review: Introduces Memory Pharmaceuticals to our Bluechips Radar ... (M2 PressWIRE Via Thomson Dialog NewsEdge) International Stock Targets is a world renowned independent research firm, based in Johannesburg, South Africa. On Tuesday, February 19th, 2008...                    

comments

Memory Pharmaceuticals Co(GAAP) (MEMY.GP) Weekly Earnings Information

pharmiweb.co.uk     Feb 17, 2008   11 related          

Macro World Investor ... Released : Sunday, February 17, 2008 2:48 AM Company: Memory Pharmaceuticals Co(GAAP) (MEMY.GP) Actual EPS for FY End (12/2006): -0.70 Current FY High EPS Estimate: -0.45 Current FY Low EPS Estimate: -0.49 Current FY Consensus Estimate: -0.47...                    

comments